Berallo, Jarad Sean Q.

HRN: 27-96-10  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/16/2025
CO-AMOXICLAV 625MG (TAB)
10/16/2025
10/23/2025
PO
625 MG/TAB
Q8H
MULTIPLE LACERATIONS OF THE FACE
Checking Initial Appropriateness 

 Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines